Palatin Technologies, Inc. (PTN) vs TScan Therapeutics, Inc. (TCRX)
A side-by-side comparison of Palatin Technologies, Inc. and TScan Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PTN
Palatin Technologies, Inc.
$9.41HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TCRX
TScan Therapeutics, Inc.
$0.28HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — PTN vs TCRX
growth of $100 · dividends reinvested · last 5yPTN -98.6% (-57.2%/yr)TCRX -97.2% (-51.0%/yr)TCRX compounded faster over this window
PTN TCRX
PTN vs TCRX: by the numbers
- •TCRX is the larger company ($17M vs $17M market cap).
- •Both run net losses; PTN's is the smaller (-63.54% vs -1655.35% net margin).
Metrics side by side
Valuation
| Metric | PTN | TCRX |
|---|---|---|
| P/S ratio | 1.27 | 2.37 |
| P/B ratio | 2.50 | 0.24 |
Profitability
| Metric | PTN | TCRX |
|---|---|---|
| Gross margin | 99.63% | 72.24% |
| Operating margin | -65.74% | -1315.38% |
| Net margin | -63.54% | -1655.35% |
| ROE | -125.30% | -170.55% |
| ROIC | -125.44% | -79.20% |
Growth (annualized)
| Metric | PTN | TCRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 3.60% |
| Total return CAGR (5Y) | -55.41% | -48.85% |
Frequently asked
- How have PTN and TCRX total returns compared?
- Over the past 5 years, PTN delivered -55.41% and TCRX delivered -48.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.